RESUMEN
In ovariohysterectomized dogs, the uterine stump rarely causes clinical disease. However, changes could occur in this anatomic structure due to exposure to estrogen therapy. Ultrasonographic examination of the uterine stump has not been reported in dogs receiving estriol and normal dimensions for this area have not been reported for ovariohysterectomized dogs. Therefore, the aims of this study were to retrospectively evaluate records and ultrasound images from dogs receiving and not receiving (controls) estriol as well as defining a standard method to measure the uterine stump. Clinical features of dogs administered estriol were also reported. Fourteen dogs receiving estriol and 14 control dogs were included in the study. Seven dogs receiving estriol had changes associated with the external vulva, 5 were noted to be "hooded" and 3 were "prominent/swollen." Ultrasonographic transverse maximum uterine stump measurements were available for 4 dogs receiving estriol (median 0.81 cm, range 0.53-1.4). The maximum uterine height/aorta ratio was available for only 2 dogs receiving estriol (0.9 and 0.6). The median transverse maximum height of the uterine stump noted in the control group was 0.43 cm (range 0.28-0.52 cm); The maximal uterine height/aorta ratio was a median of 0.48 in the control group (range 0.32-1.1). Normal values for the uterine stump measurements can be standardized to the distal aorta for consistency. Vulvar enlargement was the most common physical examination change in our dogs receiving estriol. Routine screening, including ultrasonography is not usually indicated for dogs receiving estriol, but can be tailored to the individual patient.
Asunto(s)
Estriol/farmacología , Histerectomía/veterinaria , Ovariectomía/veterinaria , Útero/efectos de los fármacos , Animales , Enfermedades de los Perros/tratamiento farmacológico , Perros , Estriol/administración & dosificación , Femenino , Estudios Retrospectivos , Ultrasonografía/veterinaria , Incontinencia Urinaria/tratamiento farmacológico , Incontinencia Urinaria/veterinaria , Útero/diagnóstico por imagen , Útero/cirugíaRESUMEN
OBJECTIVE: To evaluate the efficacy of low-dose, intravaginal estriol ovules in postmenopausal women with stress urinary incontinence (SUI) before and after transobturator tape (TOT) placement, assessing vaginal health, quality of life (QoL), and sexual function. METHODS: Ninety-six postmenopausal women affected by SUI and scheduled for TOT placement were enrolled. Women were randomized and divided into two groups through 1:1 at baseline (T0): study group (group A, nâ=â48) and control group (group B, nâ=â48). Group A was treated daily for 16 weeks with an intravaginal ovule containing 0.03âmg estriol. Vaginal epithelium maturation, QoL, and sexual function were investigated by using the Vaginal Maturation Index (VMI), Short Form-36 (SF-36) questionnaire, and Female Sexual Function Index (FSFI) questionnaire at baseline (T0), before surgery (T1), and 8 weeks after surgery (T2), respectively. RESULTS: Thirty-six women from group A and 44 women from group B completed the study. The VMI improved in group A at T1 (T1 [43.1] vs T0 [38.1]; Pâ=â0.04) and T2 (T2 [47.8] vs T0 [38.1]; Pâ=â0.001). The physical index score of the QoL improved only after surgery in group A (T2 [49.4] vs T0 [39.7]; Pâ=â0.001). On the contrary, the mental index score improved at T1 [T1 (41.9) vs T0 (37.9), (Pâ=â0.02)] and at T2 [T2 (49.6) vs T0 (37.9), Pâ=â0.001]. Group B had improvement of the physical (45.6 vs 39.4; Pâ=â0.001) and mental (43.6 vs 38.9; Pâ=â0.002) index scores at T2. Sexual function improved in group A at T1 (13.9 vs 18.6; Pâ=â0.001) and at T2 (13.9 vs 25.2; Pâ=â0.001), and in group B at T2 (14 vs 17.2; Pâ=â0.001). Moreover, it improved after TOT placement more in group A than in group B (Pâ=â0.001). CONCLUSIONS: Ultralow-dose topical vaginal ovules containing 0.03âmg estriol administrated before and after TOT placement could improve the vaginal epithelium maturation of postmenopausal women affected by SUI. Moreover, vaginal estriol ovules also improved the surgical outcome investigated by SF-36 and FSFI.
Asunto(s)
Estriol/administración & dosificación , Complicaciones Posoperatorias/tratamiento farmacológico , Disfunciones Sexuales Fisiológicas/tratamiento farmacológico , Cabestrillo Suburetral/efectos adversos , Incontinencia Urinaria de Esfuerzo/cirugía , Administración Intravaginal , Femenino , Humanos , Persona de Mediana Edad , Posmenopausia , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/psicología , Periodo Posoperatorio , Calidad de Vida , Disfunciones Sexuales Fisiológicas/etiología , Disfunciones Sexuales Fisiológicas/psicología , Encuestas y Cuestionarios , Resultado del Tratamiento , Incontinencia Urinaria de Esfuerzo/psicología , Vagina/patologíaRESUMEN
Vulvo-vaginal atrophy (VVA) is a chronic condition affecting many postmenopausal women. Local estrogen treatment is recommended. Evaluating efficacy and safety of long-term VVA treatment with ultra-low-dose estriol gel, 120 postmenopausal VVA women were enrolled in a prospective study. They received the first cycle of 1 g/day vaginal gel containing 50 µg estriol for 3 weeks and then twice a week for 12 weeks. Moderate or severe VVA women received a second treatment cycle reaching treatment of 30 weeks. Vaginal pH measurement, subjective symptoms, and objective signs assessment of VVA, endometrial thickness and adverse events (AE) were recorded. Of the 99 women, completing the first phase, 43% experienced a complete VVA symptom relief, and 65% presented a milder VVA degree. After 30 weeks, VVA signs significantly improved (p<.01) compared with baseline and first phase results; total objective symptom evaluation including Schiller's test, flattening of folds and vaginal pH significantly improved (p<.01). At study endpoint, none of the patients had severe VVA, 93% had a positive response, 75% had a complete symptom, and sign resolution. No treatment-related endometrial AE were observed. Postmenopausal VVA long term-treatment with ultra-low-dose estriol vaginal gel is safe and effective.
Asunto(s)
Estriol/administración & dosificación , Vagina/patología , Enfermedades Vaginales/tratamiento farmacológico , Vulva/patología , Enfermedades de la Vulva/tratamiento farmacológico , Administración Tópica , Adulto , Anciano , Atrofia/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Estriol/efectos adversos , Femenino , Humanos , Cumplimiento de la Medicación/estadística & datos numéricos , Persona de Mediana Edad , Posmenopausia/efectos de los fármacos , Factores de Tiempo , Resultado del Tratamiento , Vagina/efectos de los fármacos , Cremas, Espumas y Geles Vaginales/administración & dosificación , Cremas, Espumas y Geles Vaginales/efectos adversos , Vulva/efectos de los fármacosAsunto(s)
Dispositivos Anticonceptivos Femeninos , Estriol/farmacocinética , Terapia de Reemplazo de Hormonas/métodos , Posmenopausia/efectos de los fármacos , Administración Intravaginal , Anciano , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Estriol/administración & dosificación , Estriol/efectos adversos , Femenino , Hormona Folículo Estimulante/sangre , Voluntarios Sanos , Terapia de Reemplazo de Hormonas/efectos adversos , Humanos , Estudios Longitudinales , Hormona Luteinizante/sangre , Persona de Mediana Edad , Posmenopausia/sangre , Globulina de Unión a Hormona Sexual/análisisRESUMEN
BACKGROUND: Transdermal delivery is an alternative route for the administration of drugs. However, it requires the development of vehicles that allow the drugs to cross the layers of the skin and reach the systemic circulation. OBJECTIVE: In this study, a new transdermal vehicle was evaluated using progesterone, estradiol, estradiol + estriol (Biest) and ketoprofen administered as model drugs. METHODS: To evaluate the ex vivo permeation of the drugs, the Franz vertical diffusion cell with human skin was used. RESULTS: After 24 h, the vehicle was able to deliver 18.32 µg/cm2 of progesterone and 92.07 µg/cm2 of ketoprofen through the skin to the receptor medium. The permeation percentages were 91%, 78.8%, 48.5%, 73.2%, and 63.6%, respectively, for estradiol, estradiol (Biest), estriol (Biest), progesterone and ketoprofen. For all drugs, sufficient amounts were delivered to achieve a systemic effect, and it was also possible to decrease the amount of emulsion applied. CONCLUSION: Thus, the vehicle demonstrated a high performance and the possibility of it being used for drugs that present difficulties in regards to administration by the transdermal route.
Asunto(s)
Sistemas de Liberación de Medicamentos , Absorción Cutánea , Piel/metabolismo , Administración Cutánea , Adulto , Antiinflamatorios no Esteroideos/administración & dosificación , Combinación de Medicamentos , Estradiol/administración & dosificación , Estriol/administración & dosificación , Femenino , Humanos , Técnicas In Vitro , Cetoprofeno/administración & dosificación , Progesterona/administración & dosificaciónRESUMEN
OBJECTIVE: We updated a systematic review to evaluate the totality of evidence available for the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause (GSM) based on published randomized controlled trials. METHODS: We searched the Cochrane Library, Ovid, PubMed, Medline, Embase, and Clinicaltrials.gov for English-language articles from database inception to June 2018. Our search consolidated 2,086 potential sources to 53 full-text articles that were reviewed and found relevant to our systematic review. RESULTS: We identified 53 studies that met the inclusion criteria that evaluated the efficacy and safety of vaginal estrogen versus placebo or other hormone and nonhormone controls. Compared with placebo, all vaginal estrogens demonstrated superiority in objective endpoints and subjective endpoints of GSM, whereas some trials demonstrated superiority versus placebo in urogenital symptoms. No significant difference was observed between various dosages and dosage forms of vaginal estrogen products. Vaginal estrogen showed superiority over vaginal lubricants and moisturizers for the improvement of objective clinical endpoints of vulvovaginal atrophy but not for subjective endpoints. Unopposed vaginal estrogens seemed safe, although studies were not powered to detect a long-term estrogenic side effect. CONCLUSION: Estrogen products were found to be clinically effective for the treatment of GSM with doses as low as 4 µg. Vaginal estrogen products seem to be safe with few adverse effects, although there is a lack of long-term controlled clinical trial safety data. This review supports the use of commercially available vaginal estrogen therapies as an effective and safe first-line therapy for the treatment of moderate-to-severe GSM.
Asunto(s)
Atrofia/tratamiento farmacológico , Estrógenos/administración & dosificación , Menopausia , Administración Intravaginal , Estriol/administración & dosificación , Terapia de Reemplazo de Estrógeno , Femenino , Humanos , Ácido Hialurónico/administración & dosificación , Lubricantes/administración & dosificación , Vagina/patologíaRESUMEN
INTRODUCTION: The aim of this study was to examine the association between plasma hormone concentrations, cervical length, and preterm delivery in twin pregnancies, including the effect of progesterone treatment. MATERIAL AND METHODS: This study included 191 women pregnant with twins from a randomized placebo-controlled trial. A baseline blood sample was collected at 18-24 weeks before treatment with vaginal progesterone (n = 95) or placebo pessaries (n = 96), and 167 (87.4%) women had a second sample collected after 4-8 weeks of treatment. At baseline, 155 (81.2%) women had their cervical length measured. Progesterone, estradiol, and unconjugated estriol concentration was measured, and the association between hormone concentrations, cervical length, and gestational age at delivery was examined. Hormone concentrations were compared in the placebo and progesterone group. Statistical analysis included Spearman's rho, Mann-Whitney U test, Cuzick's test for trends, and linear regression analyses. RESULTS: A short cervical length was associated with preterm delivery. Cervical length and hormone concentrations were not associated (Spearman's rho; progesterone -.05, estradiol .04, estriol .08). Decreasing gestational age at delivery was associated with higher progesterone and estradiol concentrations at baseline (P trend; progesterone 0.04, estradiol 0.02) but not in the second sample or in the weekly change between samples. Progesterone treatment did not increase the progesterone concentration. CONCLUSIONS: Plasma concentrations of progesterone, estradiol, and unconjugated estriol at 18-24 weeks are not associated with cervical length or preterm delivery in twin pregnancies. Vaginal progesterone treatment does not increase the circulating progesterone concentration in twin pregnancies. Cervical length, but not hormone concentration, is predictive of preterm delivery in twin gestations.
Asunto(s)
Medición de Longitud Cervical , Estriol/sangre , Complicaciones del Embarazo/sangre , Embarazo Gemelar/sangre , Progesterona/sangre , Progestinas/sangre , Adulto , Estriol/administración & dosificación , Femenino , Humanos , Embarazo , Complicaciones del Embarazo/tratamiento farmacológico , Resultado del Embarazo , Nacimiento Prematuro/prevención & control , Progesterona/administración & dosificación , Progestinas/administración & dosificaciónRESUMEN
Estrogen replacement therapy is often recommended when female patients present with lower than normal physiologic levels, such as patients going through menopause. The physical and chemical stability of estriol 0.25 mg/g and 10 mg/g vaginal creams (VersaBase) was tested over a period of 182 days, at room temperature and refrigerated conditions, in order to determine the corresponding beyond-use date. The physical characterization consisted in observing all samples for color/appearance and odor, and testing for pH, whereas the chemical characterization consisted in ultra-performance liquid chromatography assay testing. Both vaginal creams were proven physically and chemically stable, and the ultra-performance liquid chromatography method was proven stability indicating. As a result, the beyond-use date of the estriol 0.025% to 1% vaginal creams (VersaBase), in electronic mortar and pestle plastic jars, is six months at both room temperature and refrigerated conditions.
Asunto(s)
Estriol/química , Terapia de Reemplazo de Estrógeno/métodos , Bases Oleosas/química , Administración Intravaginal , Composición de Medicamentos , Estabilidad de Medicamentos , Estriol/administración & dosificación , Femenino , Humanos , Temperatura , Factores de TiempoRESUMEN
STUDY QUESTION: Which progesterone vaginal pessary dose regimen induces adequate secretory transformation of the endometrium, in comparison with progesterone vaginal gel and placebo? SUMMARY ANSWER: The best secretory transformation of the endometrium was observed during treatment with 400 mg progesterone vaginal pessaries, administered twice daily. WHAT IS KNOWN ALREADY: Vaginally administered progesterone is widely used for luteal phase support (LPS) in assisted reproductive techniques (ART). Although several vaginal formulations using various doses are available, little is known on the impact of formulation and doses at the endometrial level. STUDY DESIGN, SIZE, DURATION: The study had a randomised, observer-blind design and comprised two parts. The participants used study medication during two or three treatment periods, separated by washout periods. Subjects in Part 1 (n = 61 treated) received 200 mg progesterone vaginal pessaries twice daily (bid), 400 mg pessaries bid and the comparator 90 mg progesterone vaginal gel once daily (od) in a 3-way crossover design. Subjects in Part 2 (n = 64 treated) received 100 mg pessaries bid in one period and 400 mg pessaries od in the other period in a 2-way crossover design. A subgroup of these subjects (n = 22 treated) received placebo vaginal pessaries bid in a third period in a non-randomised manner. The study was performed from May 2012 until April 2013. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study was performed at a clinical research centre in healthy female volunteers of reproductive age. The subjects used 2 mg estradiol bid for 24 days in each treatment cycle. Progesterone or placebo was administered vaginally from Day 15 onwards during 10 days. In each treatment period, an endometrial biopsy for histological evaluation was performed on Day 23 and pharmacokinetic parameters were determined after the first progesterone dose on Day 15 and after the last dose on Day 24. MAIN RESULTS AND THE ROLE OF CHANCE: Frequencies of (early and late) secretory transformation of the endometrium, i.e. adequate responses, during treatment with 200 mg and 400 mg vaginal pessaries bid were comparable with those during 90 mg vaginal gel treatment (90-94%), whereas lower secretory transformation rates were observed during treatment with 100 mg bid and 400 mg od (64-75%). At the time of the endometrial biopsy in the cycle the late secretory state of the endometrium, which is characteristic of adequate luteal support, was observed more often with 400 mg pessaries bid (90%) than with vaginal gel (82%) and with lower pessary doses (64-78%). Pharmacokinetic parameters after repeated dosing of vaginal pessaries showed a dose-dependent, but not dose-proportional, increase of plasma progesterone levels. The lowest incidence of bleeding and spotting was reported during treatment with 400 mg pessaries bid. LIMITATIONS REASONS FOR CAUTION: The primary outcome parameter, rate of secretory transformation of the endometrium, is a surrogate for endometrial receptivity and for the actual clinical efficacy. WIDER IMPLICATIONS OF THE FINDINGS: Delivery of progestesterone through 400 mg pessaries bid is an effective alternative method for luteal support in ART. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by Actavis Group PTC ehf., Iceland, part of Teva Pharmaceuticals, and L.D. Collins. I.D. and C.K. are directors of Dinox, a contract research organisation. I.K. is Managing Director of Pharmaplex and M.W. is Managing Director of M.A.R.C.O., service organisations involved in organisation/supervision and evaluation/reporting of clinical trials. All received funding for the conduct of the study from Actavis. S.H. and Th.M. are employees of Actavis. TRIAL REGISTRATION NUMBER: EudraCT number 2012-001726-95.
Asunto(s)
Endometrio/efectos de los fármacos , Estriol/administración & dosificación , Fase Luteínica/efectos de los fármacos , Progesterona/administración & dosificación , Administración Intravaginal , Adolescente , Adulto , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Estriol/farmacocinética , Femenino , Humanos , Persona de Mediana Edad , Folículo Ovárico/diagnóstico por imagen , Pesarios , Progesterona/sangre , Progesterona/farmacocinética , Cremas, Espumas y Geles Vaginales/administración & dosificación , Cremas, Espumas y Geles Vaginales/farmacocinética , Adulto JovenRESUMEN
Why compound bioidentical hormones? Are there no similar commercial products? What is unique about the options compounding pharmacists offer compared with what is out in the marketplace? These are questions that physicians and other practitioners are asking, and it is very important that we have intelligent, well-thought answers when we respond. Times have changed, and the challenges we face today in marketing our compounded therapies are not the same as those of twenty years ago. Premarin is no longer at the top of the heap, and there are topical, commercial products that contain bioidentical estradiol, and capsules that contain the same progesterone that we use. Our compounding advantage comes from our abilities to prepare unique patient-specific products, and, very importantly, from our growing understanding of hormone receptors; we now know there are two main estrogen receptors, 1) estrogen receptor alpha and 2) estrogen receptor beta, and the growing knowledge base associated with the discovery of estrogen receptor beta is quite significant.
Asunto(s)
Andrógenos/administración & dosificación , Composición de Medicamentos/métodos , Terapia de Reemplazo de Estrógeno/métodos , Estrógenos/administración & dosificación , Progestinas/administración & dosificación , Estriol/administración & dosificación , Estriol/metabolismo , Receptor alfa de Estrógeno/metabolismo , Receptor beta de Estrógeno/metabolismo , Femenino , Humanos , Progesterona/administración & dosificación , Testosterona/administración & dosificaciónAsunto(s)
Enfermedad de Crohn/complicaciones , Perimenopausia , Evaluación de Síntomas , Anemia Perniciosa/complicaciones , Anticonceptivos Sintéticos Orales/administración & dosificación , Enfermedad de Crohn/fisiopatología , Cistitis Intersticial/complicaciones , Desogestrel/administración & dosificación , Dispareunia/tratamiento farmacológico , Estradiol/administración & dosificación , Estriol/administración & dosificación , Estrógenos/administración & dosificación , Femenino , Rubor/tratamiento farmacológico , Humanos , Menstruación/efectos de los fármacos , Menstruación/psicología , Persona de Mediana Edad , Osteoporosis/complicaciones , Perimenopausia/efectos de los fármacos , Perimenopausia/psicología , Cremas, Espumas y Geles VaginalesRESUMEN
BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant hereditary disorder resulting in vascular dysplasia and formation of arteriovenous malformations. Recurrent epistaxis is a hallmark of the disease. An array of medical therapies are used in this patient population, but robust evidence-based recommendations regarding the medical treatment of epistaxis are lacking. This systematic review was performed to look at the current literature and make meaningful evidence-based recommendations. METHODS: A search of the Ovid MEDLINE, Embase, and Cochrane databases was conducted by a research librarian. Abstracts in the English language and published in a peer-review journal were reviewed for relevance and inclusion. PRISMA guidelines were followed. RESULTS: Eighteen studies met the inclusion criteria. In a few small studies, thalidomide was shown to consistently improve severity and frequency of epistaxis and improve hemoglobin concentrations while decreasing the need for transfusion. Tranexamic acid appeared to only impact the epistaxis severity score and not other clinical outcomes. Selective estrogen modulators (SERMs), propranolol, rose geranium oil, and N-acetylcysteine, have demonstrated promising efficacy in small trials. CONCLUSION: Appropriate medical therapies for epistaxis outcomes in HHT remain undefined, and there is no "gold standard." Many of the studies are small and the data reported are heterogeneous, and therefore the ability to make strong evidence-based recommendations is limited. However, many different medications appear to be promising options.
Asunto(s)
Epistaxis/tratamiento farmacológico , Telangiectasia Hemorrágica Hereditaria/complicaciones , Administración Oral , Administración Tópica , Inhibidores de la Angiogénesis/uso terapéutico , Epistaxis/etiología , Estriol/administración & dosificación , Terapia de Reemplazo de Estrógeno/métodos , Medicina Basada en la Evidencia , Femenino , Humanos , Masculino , Recurrencia , Moduladores Selectivos de los Receptores de Estrógeno/uso terapéutico , Talidomida/uso terapéutico , Ácido Tranexámico/uso terapéuticoRESUMEN
In recent years, a vast quantity of clinical data has been accumulated on the pathophysiology of symptomatic vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM) in peri- and postmenopausal women and on the treatment options for these conditions. Guidelines from several societies have recently been updated in favor of VVA/GSM vaginal therapy with the lowest possible doses of estrogens. The combination of a vaginal ultra-low dose of 0.03 mg of estriol (E3) and lyophilized, viable Lactobacillus acidophilus KS400 (0.03 mg-E3/L) is a unique product with a dual mechanism of action supporting not only the proliferation and maturation of the vaginal epithelium, but also restoration of the lactobacillary microflora. It has been demonstrated efficiently to establish and maintain a healthy vaginal ecosystem. Use of this combination considerably improves the clinical signs and symptoms as well as the quality of life of menopausal women suffering from vaginal atrophy. This combination therapy is well tolerated with a low overall incidence of side-effects and negligible estriol absorption. Based on recent scientific evidence and current treatment guidelines, the 0.03 mg-E3/L combination could be considered one of the options for the treatment of symptomatic vaginal atrophy in aging menopausal women.
Asunto(s)
Estriol/administración & dosificación , Lactobacillus acidophilus , Menopausia , Enfermedades Vaginales/terapia , Administración Intravaginal , Atrofia , Terapia Combinada , Femenino , Humanos , Persona de Mediana Edad , Calidad de Vida , Disfunciones Sexuales Fisiológicas/terapia , Vagina/microbiología , Vagina/patologíaRESUMEN
OBJECTIVES: OAB is a common finding in postmenopausal women. Hypoestrogenism is the root cause of many signs and symptoms of Genitourinary Syndrome of Menopause (vaginal dryness, atrophy, dyspareunia, urinary disorders, etc.). As such the aim of this study was to evaluate the urodynamic effects of ultralowdose estriol vaginal gel formulation to treat women with Genitourinary Syndrome of Menopause and Overactive Bladder Syndrome. STUDY DESIGN: This open-labeled, single center, prospective study involved 37 women with OAB recruited in our Urogynecological Unit between January and July 2016. They received estriol 50â¯mcg/g vaginal gel, one applicator-dose per day for 3 weeks followed by one dose twice a week for 12 weeks. Objective and subjective parameters were evaluated before and after treatment through the urodynamic examination, Overactive Bladder symptom score and Short Form Health Survey-36 questionnaires. RESULTS: Vaginal atrophy symptoms and signs as well as the overactive bladder subjective symptom parameter improved significantly. Urodynamic evaluation showed significant improvement in first desire to void and maximum cystometric capacity after estriol usage. Patients who had detrusor overactivity did not show any improvement for this parameter after treatment. The voiding function parameters did not significantly change. Short form-36 showed a better quality of life after treatment especially for the emotional role, as well as mental and general health. CONCLUSIONS: A local ultra-low dose concentration of estriol could be effective in women with vaginal atrophy and Overactive Bladder Syndrome for improving both subjective symptoms and urodynamic parameters of storage function not affecting voiding function.
Asunto(s)
Estriol/uso terapéutico , Estrógenos/uso terapéutico , Enfermedades Urogenitales Femeninas/tratamiento farmacológico , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Vejiga Urinaria/efectos de los fármacos , Urodinámica/efectos de los fármacos , Sistema Urogenital/efectos de los fármacos , Anciano , Anciano de 80 o más Años , Esquema de Medicación , Estriol/administración & dosificación , Estriol/efectos adversos , Estrógenos/administración & dosificación , Estrógenos/efectos adversos , Femenino , Enfermedades Urogenitales Femeninas/fisiopatología , Humanos , Menopausia , Persona de Mediana Edad , Dolor/inducido químicamente , Pacientes Desistentes del Tratamiento , Dolor Pélvico/inducido químicamente , Estudios Prospectivos , Autoinforme , Índice de Severidad de la Enfermedad , Vejiga Urinaria/fisiopatología , Vejiga Urinaria Hiperactiva/fisiopatología , Sistema Urogenital/fisiopatología , Vagina/efectos de los fármacos , Vagina/inervación , Cremas, Espumas y Geles Vaginales/administración & dosificación , Cremas, Espumas y Geles Vaginales/efectos adversos , Cremas, Espumas y Geles Vaginales/uso terapéuticoRESUMEN
AIMS: To evaluate the effect of adjuvants during intensive vaginal dilator therapy for functional and anatomical neovagina creation in women with Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH). METHODS: This retrospective cohort study included 75 women with MRKH undergoing intensive vaginal dilator treatment between 2000 and 2014. One specialist nurse performed non-surgical vaginal dilation aided by adjuvants, during inpatient admissions for several dilation sessions per day. Following discharge, women continued dilation at home and were advised to attend fortnightly follow-up appointments. RESULTS: Outcomes from 68 women were analysed. The median age of starting treatment was 18 years (range: 13-36). There was a mean of 3 days per admission (range 1-5) with a median of 10 dilation sessions per admission. Adjuvant treatment was used by 48/68 (71%) women: oestriol cream 29/68 (43%), 50:50 nitrous oxide and oxygen 44/68 (65%), diazepam 8/68 (12%), lidocaine ointment 26/68 (39%), paracetamol 35/68 (51%) and naproxen 2/68 (3%). There were no statistically significant differences for changes in vaginal parameters. Women receiving adjuvants had a median increase of 4.5 cm (0.5-7 cm) in neovaginal length compared with women not receiving adjuvants who had a median increase of 3.25 cm (0-7 cm) during intensive treatment. Women who received adjuvants tolerated more dilation sessions per day (10 vs 6.5 median sessions respectively) than those who did not (P < 0.001). Of those with documented length at discharge, 42/56 (75%) women had an anatomical neovagina of 7 cm or greater length. CONCLUSIONS: Vaginal dilation delivered by intensive treatment and supplemented by adjuvant treatments in a multi-disciplinary centre is a rapid and effective method for creation of a neovagina in women with MRKH.
Asunto(s)
Trastornos del Desarrollo Sexual 46, XX/terapia , Anomalías Congénitas/terapia , Dilatación , Conductos Paramesonéfricos/anomalías , Vagina/anatomía & histología , Trastornos del Desarrollo Sexual 46, XX/tratamiento farmacológico , Administración Intravaginal , Adolescente , Adulto , Terapia Combinada , Anomalías Congénitas/tratamiento farmacológico , Dilatación/efectos adversos , Estriol/administración & dosificación , Femenino , Humanos , Estudios Retrospectivos , Resultado del Tratamiento , Adulto JovenRESUMEN
OBJECTIVE: The aim of the study was to evaluate efficacy of fractional CO2 vaginal laser treatment (Laser, L) and compare it to local estrogen therapy (Estriol, E) and the combination of both treatments (Laser + Estriol, LE) in the treatment of vulvovaginal atrophy (VVA). METHODS: A total of 45 postmenopausal women meeting inclusion criteria were randomized in L, E, or LE groups. Assessments at baseline, 8 and 20 weeks, were conducted using Vaginal Health Index (VHI), Visual Analog Scale for VVA symptoms (dyspareunia, dryness, and burning), Female Sexual Function Index, and maturation value (MV) of Meisels. RESULTS: Forty-five women were included and 3 women were lost to follow-up. VHI average score was significantly higher at weeks 8 and 20 in all study arms. At week 20, the LE arm also showed incremental improvement of VHI score (Pâ=â0.01). L and LE groups showed a significant improvement of dyspareunia, burning, and dryness, and the E arm only of dryness (Pâ<â0.001). LE group presented significant improvement of total Female Sex Function Index (FSFI) score (Pâ=â0.02) and individual domains of pain, desire, and lubrication. In contrast, the L group showed significant worsening of pain domain in FSFI (Pâ=â0.04), but FSFI total scores were comparable in all treatment arms at week 20. CONCLUSIONS: CO2 vaginal laser alone or in combination with topical estriol is a good treatment option for VVA symptoms. Sexual-related pain with vaginal laser treatment might be of concern.
Asunto(s)
Estriol/uso terapéutico , Vagina/patología , Enfermedades Vaginales/tratamiento farmacológico , Administración Intravaginal , Anciano , Atrofia , Método Doble Ciego , Estriol/administración & dosificación , Femenino , Humanos , Láseres de Gas , Persona de Mediana Edad , Posmenopausia , Resultado del Tratamiento , Enfermedades Vaginales/radioterapia , Escala Visual AnalógicaRESUMEN
OBJECTIVES: To evaluate the efficacy and safety of estriol for the treatment of vulvovaginal atrophy in postmenopausal women. METHODS: A systematic literature review was performed. We searched the following electronic databases: Medline, Cochrane, Embase, Lilacs, CINHAL and Google Scholar. The studies selected included controlled clinical trials and quasi-experimental studies. Selections were made in pairs and independently, first by title and abstract and then complete texts. RESULTS: We identified 188 studies, 22 of which met the inclusion criteria; 13 were controlled clinical trials and nine were quasi-experimental, and 1217 women were included. These studies confirmed the efficacy of local estrogens to treat symptoms of vulvovaginal atrophy with few adverse effects reported. Following treatment, serum estriol levels rose, peaking at 1 h. At the 6-month follow-up, there was no increase in serum estriol in treated women. CONCLUSIONS: The available evidence (of low and moderate quality) shows that, when administered vaginally, estriol preparations appear to be safe for women who have risk factors related to systemic estrogen therapy.
Asunto(s)
Estriol/administración & dosificación , Enfermedades Urogenitales Femeninas/tratamiento farmacológico , Posmenopausia , Vagina/patología , Vulva/patología , Administración Intravaginal , Adulto , Anciano , Anciano de 80 o más Años , Atrofia/tratamiento farmacológico , Endometrio/efectos de los fármacos , Estriol/efectos adversos , Estriol/sangre , Femenino , Humanos , Concentración de Iones de Hidrógeno , MEDLINE , Persona de Mediana Edad , Vagina/químicaRESUMEN
OBJECTIVE: To evaluate the efficacy of low concentrations of vaginal estriol gel in postmenopausal women with pelvic static disorders before and after vaginal surgical treatment, assessing vaginal health, sexual function, and quality of life (QoL). METHODS: Women affected by genital prolapse were enrolled. Vaginal health, QoL, and sexual function were investigated at baseline (T0), before surgery (T1), and 13 weeks after surgery (T2). At baseline, participants were randomized 1:1. Women in group A (38 women) were treated daily with vaginal gel containing 50âµg estriol for 12 weeks and women in group B (37 women) did not receive any estrogen treatment. After this period and before surgery, a first examination was carried out (T1). One week after surgical treatment, group A underwent randomization 1:1 to group A1 repeating estriol vaginal gel for 12 weeks, and group A2 discontinuing the estrogen treatment. The second follow-up examination (T2) was performed at the 13th week after surgery. RESULTS: All aspects of vaginal health improved in group A on estriol before surgery with respect to baseline (Pâ<â0.001). After surgery, 17 participants of group A1, 16 of group A2, and 30 of group B completed the study. Group A1 (on estriol plus surgery) further improved with respect to the presurgery estriol treatment (Pâ<â0.01). Moreover, group A2 (T2) experienced a worsening of vaginal health versus intragroup presurgery estriol treatment (Pâ<â0.01), and versus intergroup surgical estriol treatment (Pâ<â0.05). QoL improved in women only after surgery, with (Pâ<â0.01) or without (Pâ<â0.05) estriol treatment. Finally, the sexual function of participants on estriol before surgery did not change. On the contrary, it improved after surgery in both participants on estriol (Pâ<â0.001) and without estriol (Pâ<â0.01). Moreover, surgical estriol participants had a better score than surgical no-estriol participants (Pâ<â0.05). CONCLUSIONS: Estriol vaginal gel (0.005%) administration significantly improved the vaginal health of natural postmenopausal women before and after vaginal surgery. Both sexual health and QoL also significantly improved after surgery.
Asunto(s)
Estriol/administración & dosificación , Posmenopausia , Enfermedades Vaginales/tratamiento farmacológico , Atrofia/tratamiento farmacológico , Femenino , Humanos , Entrevistas como Asunto , Persona de Mediana Edad , Prolapso de Órgano Pélvico/cirugía , Periodo Posoperatorio , Calidad de Vida , Encuestas y Cuestionarios , Resultado del Tratamiento , Vagina/patología , Cremas, Espumas y Geles Vaginales , Enfermedades Vaginales/psicologíaRESUMEN
AIM: Subjectively and objectively assess stress urinary incontinence (SUI) symptoms before and after topical oestrogen therapy. METHODS: A prospective study was performed in 3 centres in South-Africa, Australia and the Netherlands. Postmenopausal women with SUI were treated with topical oestriol cream for 6 weeks. The primary subjective outcome was the Patient's Global Impression of Improvement (PGI-I) scale. The primary objective outcome was vaginal pH. Secondary subjective outcomes were: the International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form, the Incontinence Impact Questionnaire, the Urogenital Distress Inventory (UDI-6) and the most bothersome symptom approach. Secondary objective outcome was the erect cough pad test. Compliance was scored. RESULTS: A total of 68 women were enrolled. Half of the participants reported improvement on the PGI-I scale after treatment. Vaginal pH was significantly lower after treatment (median 5.3 (interquartile range (IQR) 4.5-6.0) vs. 5.0 (4.4-5.4), p = 0.002). Improvement on the UDI stress domain was observed (p = 0.01). No statistically significant differences were found in the other subjective outcomes. Baseline and repeat cough pad tests demonstrated a wide variation with no significant difference. Compliance was high (median 100 (IQR 83-100%)). CONCLUSION: Topical oestriol cream during 6 weeks improved quality of life and vaginal pH but no other objective measures of incontinence.